Drug treatment may treat portal hypertension, a potentially life-threatening condition linked to cirrhosis and other chronic liver diseases, stated Mayo Clinic researchers. The study was posted in March on Gastroenterology, the online journal of the American Gastroenterological Association. Print publication is scheduled for July.
While therapies have been available to treat some forms of liver disease, including hepatitis C and autoimmune hepatitis, options have been more limited for treating portal hypertension, a condition where there is an increase in pressure within the portal vein that carries blood from abdominal organs to the liver. Portal hypertension is associated with cirrhosis and other chronic liver diseases.
Portal Hypertension
Find the facts of Portal Hypertension and TIPS including Causes, Symptoms, Diagnosis & Treatment and more information.
Advertisement
‘Sivelestat and similar drugs constitute a potential means to decrease portal hypertension in patients with chronic liver disease.’
Tweet it Now
According to the study, the drug sivelestat may effectively lower portal hypertension, improving symptoms and outcomes for those patients. The study results were obtained from mouse models but have since been confirmed in liver samples from humans, according to Vijay Shah, M.D., a Mayo Clinic gastroenterologist and senior author.
"This was an exciting confirmation of our findings and their applicability to human disease," Dr. Shah says. "Sivelestat has been safely used in humans with acute lung injury and bronchopulmonary dysplasia."
![Acute on Chronic Bleeding : New Type of Gastrointestinal Bleeding Identified]( "Acute on Chronic Bleeding : New Type of Gastrointestinal Bleeding Identified")
A previously unidentified condition with new symptoms or signs of acute bleeding has been identified.
The Mayo study showed that deposits of fibrin -- microvascular blood clots -- contributed to portal hypertension, and inflammatory cells known as neutrophils contributed to the formation of fibrin. By inhibiting neutrophil function with sivelestat, they were able to decrease portal hypertension.
"Neutrophils had not previously been identified as significant drivers of portal hypertension," says Moira Hilscher, M.D., the paper's first author. Results were verified in two different models of chronic liver disease.
"The study paves the way for developing new drugs and repurposing of existing compounds to target inflammation in the liver driven by disease-related mechanical forces," says Dr. Hilscher. "Given the increasing prevalence of advanced liver disease due to alcohol and obesity, this is clearly an unmet need."
Source: Eurekalert
Acute on Chronic Bleeding : New Type of Gastrointestinal Bleeding Identified
A previously unidentified condition with new symptoms or signs of acute bleeding has been identified.
Advertisement
The Mayo study showed that deposits of fibrin -- microvascular blood clots -- contributed to portal hypertension, and inflammatory cells known as neutrophils contributed to the formation of fibrin. By inhibiting neutrophil function with sivelestat, they were able to decrease portal hypertension.
"Neutrophils had not previously been identified as significant drivers of portal hypertension," says Moira Hilscher, M.D., the paper's first author. Results were verified in two different models of chronic liver disease.
"The study paves the way for developing new drugs and repurposing of existing compounds to target inflammation in the liver driven by disease-related mechanical forces," says Dr. Hilscher. "Given the increasing prevalence of advanced liver disease due to alcohol and obesity, this is clearly an unmet need."
Source: Eurekalert
Gum Disease Treatment Can Improve Clinical Outcomes in Cirrhosis Patients
Regular oral care to treat gum disease (periodontitis) can alter gut bacteria and reduce inflammation and cognitive problems in cirrhosis patients.
Advertisement
 Aleglitazar may be Effective for the Treatment of Liver CirrhosisAleglitazar, an investigational drug, appears to be an effective treatment for liver cirrhosis. Treatment with aleglitazar reduces inflammation, vasoconstriction, angiogenesis, mucosal disruption, and tumor necrosis factor (TNF). | Advertisement
|
Advertisement
Recommended Reading
Latest Research News
Does omega-3 help Alzheimer's patients? A new form of omega-3 helped restore specific markers of eye health in mice bred with aspects of early-onset Alzheimer's disease.
Drugs used to inhibit the physiological responses for allergic reactions lessen osteoarthritis risk, revealed research.
The International Space Station will be used to carry out experiments seeking to improve understanding of incurable child brain tumors and the muscle aging process.
How many people in the UK have misophonia? In a representative sample study, most people had at least some irritation upon hearing trigger sounds.
Routine eye-checkups and mass screenings enable early diagnosis and treatment of glaucoma. Late-stage glaucoma diagnosis leads to blindness.